Examples of 'studied in patients with hepatic' in a sentence
Meaning of "studied in patients with hepatic"
studied in patients with hepatic: conducted research within individuals affected by liver conditions
How to use "studied in patients with hepatic" in a sentence
Basic
Advanced
studied in patients with hepatic
Busulfan has not been studied in patients with hepatic impairment.
The pharmacokinetics of emtricitabine has not been studied in patients with hepatic impairment.
Cetrorelix has not been studied in patients with hepatic impairment and caution is therefore warranted.
The pharmacokinetics of emtricitabine have not been studied in patients with hepatic impairment.
Cerdelga has not been studied in patients with hepatic impairment.
The pharmacokinetics of Truvada and emtricitabine have not been studied in patients with hepatic impairment.
Humira has not been studied in patients with hepatic or renal impairment.
Hepatic impairment, The pharmacokinetics of enfuvirtide have not been studied in patients with hepatic impairment.
Adalimumab has not been studied in patients with hepatic or renal impairment.
The pharmacokinetics of enfuvirtide have not been studied in patients with hepatic impairment.
Numient has not been studied in patients with hepatic impairment.
The safety and efficacy of Soliris have not been studied in patients with hepatic impairment.
Macugen has not been studied in patients with hepatic impairment.
The safety and efficacy of Perjeta have not been studied in patients with hepatic impairment.
Ilaris has not been studied in patients with hepatic impairment.
The safety and efficacy of YERVOY have not been studied in patients with hepatic impairment.
Yellox has not been studied in patients with hepatic disease or renal impairment.
Hepatic impairment Rilonacept Regeneron has not been studied in patients with hepatic impairment.
Thiotepa has not been studied in patients with hepatic impairment.
Hepatic impairment, the pharmacokinetics of Atripla have not been studied in patients with hepatic impairment.
GANFORT has not been studied in patients with hepatic or renal impairment.
Pegaptanib pharmacokinetics have not been studied in patients with hepatic impairment.
SPRYCEL has not been studied in patients with hepatic or renal impairment.
Busilvex as well as busulfan has not been studied in patients with hepatic impairment.
NEVANAC has not been studied in patients with hepatic disease or renal impairment.
Atazanavir with ritonavir has not been studied in patients with hepatic impairment.
Plegridy has not been studied in patients with hepatic impairment see section 4.4.
Hepatic impairment Lucentis has not been studied in patients with hepatic impairment.
Crizotinib has not been studied in patients with hepatic impairment.
The safety and efficacy have not been studied in patients with hepatic impairment.
Praxbind has not been studied in patients with hepatic impairment.
Luminity has not been specifically studied in patients with hepatic impairment.
Lucentis has not been studied in patients with hepatic impairment.
This medicinal product has not been studied in patients with hepatic impairment.
Spinraza has not been studied in patients with hepatic impairment.
Rilonacept Regeneron has not been studied in patients with hepatic impairment.
Inbrija has not been studied in patients with hepatic impairment.
REYATAZ with ritonavir has not been studied in patients with hepatic impairment.
Zynteglo has not been studied in patients with hepatic impairment.
The pharmacokinetics of Truvada have not been studied in patients with hepatic impairment.
Daclizumab has not been studied in patients with hepatic impairment.
The PK of decitabine have not been formally studied in patients with hepatic impairment.
Strimvelis has not been studied in patients with hepatic impairment.
The pharmacokinetics of Atripla have not been studied in patients with hepatic impairment.
Nelarabine has not been studied in patients with hepatic impairment.
Safety and efficacy of Xofigo have not been studied in patients with hepatic impairment.
Reslizumab has not been studied in patients with hepatic impairment.
The medicinal product has not been studied in patients with hepatic or renal impairment.
RoActemra has not been studied in patients with hepatic impairment.
TREVICTA has not been studied in patients with hepatic impairment.
You'll also be interested in:
Examples of using Hepatic
Show more
Progressive renal or hepatic end organ dysfunction
Hepatic toxicity has been associated with acetaminophen
Monitoring of the hepatic function is also recommended
Examples of using Patients
Show more
Patients at the very heart of our mission
We have the best patients in the world
Patients also pay for essential drugs
Examples of using Studied
Show more
This subject is studied for five years
Studied all about you quiet guys
It has not been studied in these age groups
